FDA To Centocor: Show Me The REMS For Ustekinumab
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
After an earlier three-month delay of its ustekinumab user fee date, Centocor is facing yet another setback in getting FDA approval for the potentially first-in-class monoclonal antibody to treat chronic moderate to severe plaque psoriasis in adults